# Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

> **NCT04040361** · PHASE2 · UNKNOWN · sponsor: **Masahiro Tsuboi** · enrollment: 24 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IB
- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage ⅢA

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ramucirumab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04040361
- **Lead sponsor:** Masahiro Tsuboi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-30
- **Primary completion:** 2022-04-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040361, "Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04040361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*